SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease

Disclosure: R.S. Douglas: Consulting Fee; Self; Horizon Therapeutics plc, Immunovant, Viridian. S. Couch: None. S.T. Wester: Advisory Board Member; Self; Horizon Therapeutics plc. Consulting Fee; Self; Immunovant, Sling. B. Fowler: Consulting Fee; Self; Horizon Therapeutics plc. C. Liu: Other; Self;...

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond S, Couch, Steven, Wester, Sara T, Fowler, Brian, Liu, Catherine, Subramanian, Prem, Tang, Rosa, Nguyen, Quang T, Hsu, Kate, Karon, Michael, Stan, Marius N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554877/
http://dx.doi.org/10.1210/jendso/bvad114.1930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554877/
http://dx.doi.org/10.1210/jendso/bvad114.1930

Ejemplares similares